AU Patent

AU2017297718B2 — Pulsatile drug delivery system for treating morning akinesia

Assigned to Contera Pharma AS · Expires 2023-06-08 · 3y expired

What this patent protects

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

USPTO Abstract

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017297718B2
Jurisdiction
AU
Classification
—
Expires
2023-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Contera Pharma AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.